Other Issues:
|
 |
NeuroAIDS Report:
HIV-1 traffic: cell-free, cell-associated and other CNS activating stories
By Yuri Persidsky and Anuja Ghorpade
[Full text article]
[About AIDScience articles]
[See recent AIDScience articles] |
Hot News:
Data from new assay suggest VaxGen's AIDS vaccine induces broad immune response to HIV subtypes. VaxGen, Inc. announced that the journal Vaccine (Vaccine 20, 536-576, 2002) has published findings suggesting that the company's HIV/AIDS vaccine, AIDSVAX B/B, induces antibodies to the five most common HIV subtypes, as well as antibodies able to recognize primary isolates.
[See press release]
|
NIAID and Merck to collaborate on HIV vaccine development. The agreement would include human testing of promising candidate HIV vaccines developed by the company.
[See press release]
|
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Induction of CTLs in the intestinal mucosa, a key site of virus replication, with a mucosal AIDS vaccine ameliorates infection by SHIV in non-human primates.
Nat. Med. 7(12):1320 [Read abstract]
|
Needle exchange does not boost local crime. People who live near a needle exchange program center, which can help reduce the risk of HIV transmission among injection drug abusers, do not report greater levels of crime.
J. Acquir. Immune Defic. Syndr. 28(3):282 [Read abstract]
|
Needle exchange to prevent HIV saves money. Human issues aside, data indicate that syringe exchange is a cost-effective and cost-saving strategy for reducing HIV transmission.
J. Acquir. Immune Defic. Syndr. 28(3):273 [Read abstract]
|
XIV International AIDS Conference (Barcelona, Spain, 7-12 July 2002). Upcoming deadlines: 14 January, paper/diskette abstract submission; 21 January, online abstract submission; 1 February, scholarship applications.
[Go to conference site]
|
